A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma

Published:2007-08-14 Issue:6 Volume:61 Page:1069-1073
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Amato Robert J.,Khan Muhammad

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-007-0568-7.pdf

Reference19 articles.

1. Jemal A, Siegel R, Ward E, Thomas A, Murray T, Xu J, Thun M (2007) Cancer statistics. CA Cancer J Clin 57:43–66

2. Motzer RJ, Rini BI, Michaelson MD et al (2004) SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial [abstract]. Proc Am Soc Clin Oncol 23:A4500

3. Motzer RJ, Rini BI, Michaelson MD (2005) Phase II trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) [abstract]. J Clin Oncol 23:A4508

4. Motzer R, Michaelson MD, Redman B et al (2006) Activity of SU 11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16–24

5. Bukowski RM (2001) Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 19:148–154

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sarcomatoid renal cell carcinoma with clear cells and eosinophilia: a case report and short review of the literature;Romanian Journal of Morphology and Embryology;2021-03-17

2. TRIP13 is identified as a prognosis biomarker for renal clear cell carcinoma and promotes renal cell carcinoma cell proliferation, migration and invasion;BIOCELL;2021

3. Clinical trials on combination of repurposed drugs and anticancer therapies;Drug Repurposing in Cancer Therapy;2020

4. The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma;Expert Opinion on Investigational Drugs;2018-01-24

5. Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy;Critical Reviews in Oncology/Hematology;2015-12